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Abstract 23 
Oncolytic virotherapy can lead to systemic antitumor immunity, but the therapeutic 24 
potential of oncolytic viruses (OVs) in humans is limited due to their insufficient ability to 25 
overcome the immunosuppressive tumor microenvironment (TME). Here, we showed that 26 
locoregional oncolytic virotherapy upregulated the expression of PD-L1 in the TME, which 27 
was mediated by virus-induced type I and type II interferons (IFNs). To explore 28 
PD-1/PD-L1 signaling as a direct target in tumor tissue, we developed a novel 29 
immunotherapeutic herpes simplex virus (HSV), OVH-aMPD-1, that expressed a 30 
single-chain variable fragment (scFv) against PD-1 (aMPD-1 scFv).  The virus was 31 
designed to locally deliver aMPD-1 scFv in the TME to achieve enhanced antitumor 32 
effects. This virus effectively modified the TME by releasing damage associated molecular 33 
patterns (DAMPs), promoting antigen cross-presentation by dendritic cells, and 34 
enhancing the infiltration of activated T cells; these alterations resulted antitumor T cell 35 
activity which led to reduced tumor burdens in a liver cancer model. Compared with OVH, 36 
OVH-aMPD-1 promoted the infiltration of myeloid-derived suppressor cells (MDSCs), 37 
resulting in significantly higher percentages of CD155
+
 G-MDSCs and M-MDSCs in 38 
tumors. In combination with TIGIT blockade, this virus enhanced tumor-specific immune 39 
responses in mice with implanted subcutaneous tumors or invasive tumors. These 40 
findings highlighted that intratumoral immunomodulation with an OV expressing aMPD-1 41 
scFv could be an effective standalone strategy to treat cancers or drive maximal efficacy 42 
of a combination therapy with other immune checkpoint inhibitors. 43 
 44 
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Introduction 45 
Cancer immunotherapy has achieved great therapeutic success over the past several 46 
years., only a subset of patients benefit from immunotherapeutic regimens(1). The tumor 47 
microenvironment (TME) in many tumor types that do not respond to immunotherapy 48 
lacks infiltration of tumor-specific immune cells, lacks neoantigen expression and 49 
costimulatory signaling, and exhibits coinhibitory signaling, which restricts the efficacy of 50 
cancer therapy(2). Reversing the immunosuppressive TME is the most important 51 
challenge in the development of immunotherapeutics(3). Oncolytic viruses (OVs) can 52 
selectively replicate in tumor cells and provoke a virus-specific or tumor-specific 53 
inflammatory response in the TME(4). OVs can elicit T cell migration to tumor tissue and T 54 
cell activation, ultimately mediating local and distant immunotherapeutic efficacy(5). 55 
Oncolytic virotherapy is a promising therapeutic strategy for cancer, but further preclinical 56 
studies are needed to maximize its therapeutic efficacy(6). The antitumor efficacy of 57 
oncolytic virotherapy is significantly enhanced antitumor when combined with systemic 58 
immune checkpoint blockade, such as CTLA-4 and PD-1 blockade(7-10). However,  this 59 
raises several concerns in terms of increased toxicities for patients and medical costs to 60 
healthcare systems(11,12). To resolve these issues, investigators have designed various 61 
strategies to augment the antitumor immunity of oncolytic virotherapy, such as 62 
engineering OVs expressing cytokines, costimulatory factors, and immunomodulatory 63 
agents (13-15). 64 
In this study, we analyzed the TME alterations in response to intratumoral virotherapy in 65 
order to  select a specific immune target to guide our design our multiplexed antitumor 66 
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OV vector. We identified that the PD-1/PD-L1 pathway can be targeted to improve an 67 
oncolytic herpes simplex virus (OVH), thus constructed a recombinant OVH virus 68 
encoding a single-chain variable fragment (scFv) against PD-1 (aMPD-1 scFv), 69 
OVH-aMPD-1. We hypothesized that the intratumoral injection of OVH-aMPD-1 would 70 
induce potent oncolytic effects and revive intratumoral T cells, inducing antitumor activity. 71 
OVH-aMPD-1 increased the infiltration of CD155
+
 myeloid-derived suppressor cells 72 
(MDSCs) within the TME. TIGIT blockade improved the antitumor efficacy of 73 
OVH-aMPD-1. In summary, we demonstrated that OVH-aMPD-1 exhibited robust 74 
antitumor activity and prolonged the survival of tumor bearing mice in multiple different 75 
models. This strategy significantly augmented the efficacy of oncolytic virotherapy, 76 
providing evidence for the rational design of therapies employing this strategy for clinical 77 
investigation. 78 
 79 
Materials and Methods 80 
Mice 81 
C57BL/6 mice and BALB/c nu/nu mice were purchased from the Shanghai Slack 82 
Laboratory Animal Co., Ltd., bred and housed under specific pathogen-free conditions in 83 
the Animal Facility of Xiamen University. The mice used in studies were 4-6 weeks old 84 
unless otherwise indicated. All animal protocols were approved by the Institutional Animal 85 
Care and Use Committee at Xiamen University for animal welfare (XMULAC20150016). 86 
Cells 87 
HEK293T, Hepa1-6, and U-2 OS cells were purchased from the American Type Culture 88 
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Collection (Manassas, VA, 2015). MC38 cells were purchased from the China 89 
Infrastructure of Cell Line Resources (Beijing, China, 2018). 293T, U-2 OS and Hepa1-6 90 
cells were cultured in DMEM supplemented with 10% (v/v) fetal bovine serum (FBS) 91 
(Invitrogen). MC38 cells were cultured in 1640 medium supplemented with 10% (v/v) FBS. 92 
All cells were maintained at 37°C and 5% CO2. Hepa1-6 PD-L1
-/-
 cells were generated 93 
using the CRISPR/Cas9 method. In brief, PD-L1-targeting sgRNAs synthesized by 94 
Sangon (Shanghai, China) (sgRNA1 5’- GTATGGCAGCAACGTCACGA -3’; sgRNA2 5’- 95 
GCTTGCGTTAGTGGTGTACT -3’; and sgRNA3 5’- GGTCCAGCTCCCGTTCTACA -3’), 96 
were cloned into the lentiCRISPR v2 vector (52961, Addgene). HEK293T cells were 97 
transfected with packaging plasmids (psPAX2 (12260) and PMD2.G(12259), Addgene) 98 
and the lentiCRISPR v2 plasmid by using Lipofectamine 2000 reagent (11668019, 99 
Invitrogen) according to the manufacturer’s instructions. Virus-containing supernatants 100 
were harvested 48 h post transfection. Hepa1-6 cells were transduced with the virus 101 
supernatant for 48 h. To obtain PD-L1
-/-
 cells, these cells were stimulated with 20 ng/mL 102 
IFN-γ (752806, BioLegend) for 24 h and stained with an anti-PD-L1 antibody (124319, 103 
BioLegend), and the PD-L1-negative cells were sorted into single-cell clones. Knockout 104 
clones were verified by flow cytometry analysis for PD-L1. Hepa1-6-mRuby3 and 105 
MC38-mRuby3 cells were generated by transduction with a lentiviral vector (17477, 106 
Addgene) encoding mRuby3 or OVA. Positive clones were selected in culture medium 107 
containing 1 μg/ml puromycin (ant-pr-5, InvivoGen), and fluorescent protein expression 108 
was confirmed by flow cytometry analysis. Cell lines were not authenticated in the past 109 
year and cultured for fewer than 8 passages in indicated medium. All cell lines were 110 
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routinely tested using a Mycoplasma contamination detection kit (rep-pt1, InvivoGen). 111 
Viruses and virus generation 112 
OVH was constructed on the backbone of KOS, in which both copies of the ICP34.5 and 113 
ICP0 coding sequences were replaced by the eGFP gene and the ICP27 core promoter 114 
was replaced with a core hTERT promoter previously constructed in our laboratory. The 115 
gene encoding aMPD-1 scFv consisted of a secretion signal sequence (SP), variable light 116 
chain (VL), 3×G4S, variable heavy chain (VK) and His tag (His), which were sequentially 117 
amplified from the cDNA sequence of a rat anti-mouse PD-1 antibody (clone 32D6(16)) 118 
and assembled into pcDNA3.1 (Invitrogen) under the control of the human 119 
cytomegalovirus promoter, named pcDNA3.1-aMPD-1 scFv (Supplemental Fig. S1a and 120 
b). OVH-aMPD-1 was constructed on the backbone of OVH, in which both copies of the 121 
eGFP coding sequences were replaced by the gene encoding aMPD-1 scFv. 122 
OVH-aMPD-1-Luc was constructed on the backbone of OVH-aMPD-1, in which the gene 123 
coding luciferase was inserted into the genome between the UL37 and UL38 regions(17). 124 
The generation of recombinant virus was performed using a cell-based recombination 125 
method as previously described(17). 126 
Virus titration and replication assay 127 
The titers of amplified viruses were determined on U-2 OS monolayers using a classical 128 
plaque assay as previously described(18). Viral titers (PFU/ml) were calculated using the 129 
following formula: titer = plaque numbers×dilution fold×2. For a virus replication assay, 130 
cells were seeded in 6-cm dishes at 10
5
 cells/dish and infected with the indicated virus 131 
(0.1 PFU/cell) or mock infected. For each time point, the infected cells were harvested and 132 
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thereafter subjected to virus titration. 133 
Cytotoxicity assay 134 
In total, 6×10
6 
cells were seeded in 6-cm dishes and infected with the indicated virus (1 135 
PFU/cell) or mock infected. For each time point, cell viability was measured by detecting 136 
lactate dehydrogenase activity in the lysates using a Cytotoxicity Assay kit (G1780, 137 
Promega) according to the manufacturer’s instructions. 138 
Western blot analysis 139 
Cell lysates were prepared in RIPA lysis buffer containing a protease inhibitor cocktail 140 
(04693132001, Roche), and the protein content of the generated cell lysates was 141 
determined using the BCA protein assay (23235, Pierce). Aliquots containing 30 μg of 142 
total protein were resolved on a 12% SDS-polyacrylamide gel and transferred to 143 
nitrocellulose membrane. After membranes were blocked with 5 % BSA for 1 h, they were 144 
probed with indicated primary antibodies overnight at 4 °C, followed by incubation with the 145 
HRP-conjugated secondary antibodies (Cell Signaling Technology) for 1 h at room 146 
temperature. Finally, the blots were detected with the Lumi-Light
PLUS
 Western blotting 147 
Substrate (12015196001, Roche) and images were visualized using the ImageQuant LAS 148 
4000 system (GE Healthcare). Primary antibodies were used for probing: gD (21719, 149 
Santa Cruz), ICP0 (56985, Santa Cruz), GFP (32146, Abcam), β-actin (47778, Santa 150 
Cruz), cleaved PARP (9541S, Cell Signaling Technology), cleaved Caspase-3 (9664T, 151 
Cell Signaling Technology) as well as polyclonal anti-ICP34.5 antibodies. 152 
aMPD-1 scFv expression and purification 153 
For the production of the aMPD-1 scFv recombinant protein, the expression plasmid 154 
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pcDNA3.1-aMPD-1 scFv was transfected into HEK293T cells using PEI transfection 155 
reagents in Expi293™ Expression Medium (A1435101, Invitrogen). The medium was 156 
harvested 5 days after transfection, filtered through a 70-μm nylon filter, concentrated 157 
using ammonium sulfate precipitation and stored at 4°C. aMPD-1 scFv was purified by 158 
using Ni-NTA chromatography (17-5318-03, GE Healthcare) according to the 159 
manufacturer’s instructions. aMPD-1 scFv was eluted using 250 mM imidazole and 160 
dialyzed in PBS. The purified aMPD-1 scFv was quantified with a BCA assay (23235, 161 
Pierce) and stored at −20°C. aMPD-1 scFv proteins were subjected to SDS-PAGE. The 162 
proteins separated on the gel were visualized by silver staining (24600, Pierce) according 163 
the manufacturer’s instructions. 164 
In vitro infection experiments 165 
Cells were cultured in 6-well dishes at 6×10
6
 cells/well and infected with OVH at the 166 
indicated MOIs. The infected cells were collected for PD-L1 surface labeling at 36 h post 167 
infection and analyzed by flow cytometry analysis. The supernatants of the infected and 168 
noninfected cells were centrifuged for 5 min at 3000 rpm to remove cellular cell debris. 169 
The supernatants from the infected cells were UV inactivated with a UV Stratalinker 2400 170 
instrument (Stratagene, 360 mJ/cm
2
) for 5 min, which is sufficient to completely eliminate 171 
live virus (Supplemental Fig. S2). For supernatant transfer experiments, the inactivated 172 
supernatant was diluted 1:2 in fresh complete medium containing 10% FBS and added to 173 
fresh cells in 6-well plates. The infected cells were collected for PD-L1 surface labeling at 174 
24 h post infection and analyzed by flow cytometry. For cytokine treatment, cells were 175 
treated with 2,000 U/ml mouse IFN-α (12100, R&D Systems), IFN-γ (485-MI, R&D 176 
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Systems), CCL-4 (451-MB, R&D Systems), CCL-9 (463-MG, R&D Systems), IL1α 177 
(400-ML, R&D Systems) and TNF-α (410-MT, R&D Systems) for 24 h. For IFNAR 178 
blockade, supernatants were treated with an anti-IFNAR antibody (clone MAR1-5A3, 179 
BioXcell) at a concentration of 10 μg/ml. 180 
ELISA analysis 181 
The protein expression of aMPD-1 scFv was determined by an indirect 182 
chemiluminescence immunoassay (CEIA). Briefly, 96-well plates were coated with 100 183 
ng/well mPD-1-Fc protein (1021-PD, Sino Biological), and nonspecific binding was 184 
blocked with PBS containing 20% CBS. Purified aMPD-1 scFv protein, supernatants from 185 
OVH-aMPD-1-infected cells, or samples from OVH-aMPD-1-treated mice were added to 186 
the wells for a 1-h incubation, followed by washing and reaction with an anti-His-HRP 187 
antibody (HRP-66005, Proteintech). After the addition of 100 μl luminol substrates (Wantai 188 
BioPharm) for 5 min, the plates were measured with a chemiluminescence reader 189 
(ORION II, Berthod). For detection of aMPD-1 scFv in tumors, tumors were weighed and 190 
homogenized in 2 mL of sterile PBS in gentleMACS M tubes (130-096-335, Miltenyi 191 
Biotec)using a gentleMACS dissociator and with the running program Protein_01 (Miltenyi 192 
Biotec). The homogenates were centrifuged for 5 min at 12000 rpm and the supernatants, 193 
were assayed using the above method. Empty medium served as a control and serial 194 
dilutions of purified aMPD-1 scFv served as standards. The quantity of each experimental 195 
sample was determined using a standard curve. 196 
The reactivity of aMPD-1 scFv against PD-1 protein of human origin or mouse origin (Sino 197 
Biological) was determined by CEIA as previously described(16). To compare the blocking 198 
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activity of the commercial anti-PD1 antibodies (clone RMP1-14 and J43, BioXcell), 32D6 199 
antibodies and aMPD-1 scFv, a blocking CEIA detecting the interaction between his-PD-1 200 
and biotinylated PD-L1 was developed. Briefly, 96-well plates were coated with 50 ng/well 201 
of his-PD-1 protein (50124-M08H, Sino Biological), and nonspecific binding was blocked 202 
with PBS containing 20% CBS. 32D6 antibody or aMPD-1 scFv was first diluted from 10 203 
μg/ml in PBS containing 5% BSA, followed by two-fold serial dilutions with 8 gradients. 204 
Then, a 100 μl dilution or PBS and 100 ng/well biotinylated PD-L1 (71105, BPS 205 
Bioscience) was added to the wells for 60 min, followed by washing and reaction with 206 
Streptavidin HRP (405210, BioLegend). The plates were assayed using the above 207 
method. Control rat isotype IgG added at the same concentration served as a control. The 208 
inhibitory ratio was calculated as follows: %inhibitory = 100 × (1 − (average value for each 209 
dilution/average value for control)). Each dilution was repeated in triplicate and each test 210 
was carried out in triplicate. The results were interpreted by nonlinear, dose-response 211 
regression analysis using GraphPad Prism software. 212 
Assays for detecting Interferons 213 
Tumors from vehicle and OVH-treated Hepa1-6 tumors were lysed in RIPA lysis buffer 214 
containing a protease inhibitor cocktail (Roche). After clarification by centrifugation for 5 215 
min at 12000 rpm, supernatants were collected, and protein concentrations were 216 
normalized by the BCA protein assay (Pierce). IFN-γ, IFN-α and IFN-β concentrations in 217 
the supernatants were measured by a mouse IFN-gamma quantikine ELISA Kit (MIF00, 218 
R&D Systems), a mouse IFN-alpha ELISA (ab252352, Abcam), and a mouse IFN-beta 219 
quantikine ELISA Kit (MIFNB0, R&D Systems), separately, according to the 220 
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manufacturer’s instructions. 221 
Assays for detecting ICD determinants 222 
MC38 and Hepa1-6 cells were infected with OVH or OVH-aMPD-1 at an MOI of 1 223 
PFU/cell. After 48 h of infection, the cells were collected and stained with an ALEXA 224 
FLUOR® 647 conjugated anti-calreticulin antibody (bs-5913R-A647, Bioss) and subjected 225 
to flow cytometry to analyze calreticulin-positive cells.  Briefly, a monolayer cells was 226 
washed with PBS after trypsin digestion, and single-cell suspensions were washed twice 227 
with PBS, followed by centrifugation at 1000 rpm for 5 minutes. Cells were then stained 228 
with antibodies for 1 h in Brilliant Stain Buffer (563794, BD) on ice in the dark. Following 229 
this incubation period, stained cells were washed with PBS and then centrifuged at 1000 230 
rpm for 5 minutes. The supernatant was then aspirated and the resulting cells were 231 
resuspended in Brilliant Stain Buffer and samples were run on a BD LSRFortessa X-20 232 
according to manufacturer's recommendations, and data were analyzed by FlowJo 10. 233 
The ATP level in the supernatant was measured by the Enhanced ATP Assay Kit (S0027, 234 
Beyotime), and the HMGB1 level in the supernatant was measured by an HMGB1 ELISA 235 
kit (ST51011, TECAN) according the manufacturer’s instructions. 236 
DC purification and phagocytosis assays 237 
To generate bone marrow-derived DCs (BMDCs), single-cell suspensions of bone marrow 238 
from wild-type C57BL/6 mice were obtained according to standard protocols with minor 239 
modifications(19). Briefly, hind extremities of C57BL/6 mice were collected, soft tissues 240 
removed, and bones rinsed in 70% ethanol. After cutting the ends of femurs and tibias, 241 
bone marrow was flushed out with RPMI-1640 medium and collected. Red cells were 242 
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lysed with RBC lysis buffer (420301, BioLegend). The remaining cells were cultured in 243 
RPMI-1640 medium supplemented with 10% FBS, 50 ng/mL GM-CSF (576304, 244 
BioLegend) and 25 ng/mL IL-4 (204-IL, R&D Systems) for 7 days. CD11c
+
 DCs were 245 
purified using a Dynabeads™ Mouse DC Enrichment kit (11429D, ThermoFisher) 246 
according the manufacturer’s instructions. The isolated DCs were cultured overnight with 247 
recombinant GM-CSF and Hepa1-6-mRuby3 or MC38-mRuby3 cells pretreated with 248 
vehicle or virus for 24 h. The efficiency of DC phagocytosis is expressed as the 249 
percentage of CD11c
+
 mRuby3
+
 cells among all CD11c
+ 
CD45
+
 cells, which were counted 250 
by flow cytometry analysis. 251 
TIL isolation and flow cytometry analysis 252 
Tumor analysis was performed as previously described(20). For isolation and analysis of 253 
TILs, mice were sacrificed, and tumors were harvested for analysis 7 days after two doses 254 
of the indicated treatment were given. The tumors were removed using forceps and 255 
surgical scissors and weighed. Tumors were minced with scissors and incubated with 1 256 
mg/ml Collagenase D (11088866001, Roche) and 100 μg/ml DNase I (11284932001, 257 
Sigma) in RPMI-1640 medium supplemented with 2% FBS for 1.5 h with continuous 258 
agitation. The digestion mixture was homogenized by repeated pipetting and filtered 259 
through a 70-μm nylon filter. The single cell suspensions were washed twice with a 260 
Brilliant Stain Buffer (563794, BD) and stained with the Zombie Aqua™ Fixable Viability 261 
Kit (423102, BioLegend) to eliminate dead cells according the manufacturer’s instructions. 262 
After washing twice, the cells were stained with the corresponding antibodies, incubated 263 
for 30 min at 4°C, and then subjected to flow cytometry analysis with a BD LSRFortessa 264 
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X-20. Data were analyzed by FlowJo 10. The antibodies used for flow cytometry are listed 265 
below: anti-CD45.2 APC/Cy7 (clone 104, 109824), anti-CD3 ε Brilliant Violet 421 (clone 266 
145-2C11, 100341), anti-CD8a Alexa Fluor 700 (clone 53-6.7, 100730), anti-CD11b 267 
Brilliant Violet 650 (clone M1/70, 101239), anti-CD11c APC (clone N418, 117310), 268 
anti-Ly-6G PE/Cy7 (clone 1A8, 127618), anti-Ly-6C Alexa Fluor® 700 (clone HK1.4, 269 
128024), anti-Gr-1 FITC (clone RB6-8C5, 108406), anti-F4/80 PE/Cy5 (clone BM8, 270 
123112), anti-CD206 PerCP/Cy5.5 (clone C068C2, 141716), anti-CD69 PE (clone H1.2F3, 271 
104508), anti-ICOS PE/Cy7 (clone C398.4A, 313520), anti-CD274 Brilliant Violet 711 272 
(clone 10F.9G2, 124319), anti-CD155 PE (clone 4.24.1, 132205), anti-PD-1 Brilliant Violet 273 
785 (clone 29F.1A12, 135225), and anti-TIGIT PE/Cy7 (clone 1G9, 142108) were 274 
obtained from BioLegend; anti-CD4 FITC (clone RM4-5, 553047) was obtained from BD 275 
Pharmingen; and anti-mouse CD16/CD32 (14-0161-85) and anti-SIINFEKL/H-2Kb PE 276 
(13-5743-82) were obtained from eBioscience. 277 
T cell and tumor cell coculture assay 278 
For coculture of tumor cells and T cells, splenocytes were obtained from wild-type 279 
C57BL/6 mice, and T cells were purified from the mouse splenocytes by using the 280 
EasySep
TM
 Mouse T Cell Isolation Kit (19851, STEMCELL). Hepa1-6 cells were subjected 281 
to 40 Gy of radiation. 5×10
4
 irradiated Hepa1-6 cells and were cocultured, without rest, 282 
with the T cells in a U-bottom 96-well plate. Anti-CD3/CD28 antibody-coated beads 283 
(11456D, Thermo Fisher) and 50 U/ml recombinant mouse IL-2 (51061-MNAE, Sino 284 
Biological), together with supernatants from PBS-, OVH-, or OVH-aMPD-1 treated cells or 285 
aMPD-1 scFv, were added and incubated with the cells for 120 h. The CD4
+
 and CD8
+
 T 286 
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cells were analyzed using flow cytometry analysis. The IFNγ level in the supernatant was 287 
measured by using the mouse IFN-gamma quantikine ELISA Kit (MIF00, R&D Systems).. 288 
Tumor-specific T cells and tumor antigen presentation assay 289 
Tumors or spleens were digested and suspended in a buffer containing 4 μg/ml 290 
anti-mouse CD16/CD32 antibodies at a final concentration of 5×10
6 
cells/ml. To analyze 291 
OVA-specific T cells, single-cell suspensions were stained for 30 min at room temperature 292 
with 10 μl of T-Select H-2Kb OVA Tetramer-SIINFEKL-PE (TS-5001-1C, MBL BEIJING 293 
BIOTECH) and other indicated antibodies. To analyze cross-presentation by APCs, cells 294 
were stained with an anti-SIINFEKL/H-2Kb PE antibody (12-5743-82, eBioscience) at a 295 
1:100 dilution for 30 min at 4°C.  296 
Quantitative PCR analysis for HSV-1 DNA 297 
The tumors were removed and weighed. Total DNA was extracted from tumors by 298 
QIAamp DNA Blood MiniKit (51106, Qiagen) according to the manufacturer’s instructions. 299 
DNA content was quantitated using a NanoDrop 2000c Spectrophotometer (Thermo 300 
Scientific) and 10 ng of DNA was diluted with nuclease-free water and served as the 301 
template for each PCR reaction. Quantitative PCR analysis for HSV-1 DNA was 302 
performed using LightCycler® Systems (Roche). The probe consists of forward primers 303 
were synthesized by Sangon (Shanghai, China), 5’- GCTGGAACTACTATGACA-3’and 304 
reverse primers, 5’-CAGGATAAACTGTGTAATCTC -3’ combined with a 305 
5’-FAM-TTATCTTCACGAGCCGCAGGT-BHQ-3’-labeled probe specific for the 306 
glycoprotein D (gD) gene of HSV-1. Data collected were from a minimum of three 307 
experimental replicates all run in at least triplicate. To determine absolute DNA copy 308 
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numbers, a standard curve was run in parallel with each analysis using the serial decimal 309 
dilutions of gD gene synthesized and quantitated by Sangon (Shanghai, China), and 310 
concentrations of HSV-1 DNA in each PCR reaction were expressed as copies of gD gene 311 
(Q). The total amounts of HSV-1 DNA in tumors (copies/g tumor) were calculated using 312 
the following formula: Q×DNA content/(10ng×tumor weight). 313 
Subcutaneous xenograft model 314 
An inoculum of 5×10
6 
Hepa1-6 cells in 100 µl of sterile PBS was injected subcutaneously 315 
(s.c.) into the flank of 5-week-old female BALB/c nu/nu mice. After 10 days, the Hepa1-6 316 
tumors reached an average size of ~100 mm
3
. The mice were randomized into treatment 317 
groups immediately prior to treatment. Virus in 50 μl of sterile PBS was administered via 318 
intratumoral injection every three days for three doses in total. Tumor growth was 319 
monitored every three days by measurement with a caliper (06-664-16, Fisher Scientific). 320 
Twenty-one days after the last treatment, the mice were measured a final time. Tumor 321 
volume was calculated according to the formula: (length×width
2
) /2. 322 
Syngeneic murine cancer model 323 
For the establishment of subcutaneous Hepa1-6 tumors, an inoculum of 5×10
6
 murine 324 
Hepa1-6 cells or Hepa1-6-OVA cells in 100 µl of sterile PBS was injected s.c. into each 325 
flank of 6-week-old female C57BL/6 mice. The mice were randomized into treatment 326 
groups on day 7 or 10 following tumor inoculation, immediately before treatment. Virus in 327 
50 μl of sterile PBS was administered via intratumoral injection every three days for three 328 
doses in total. Tumor growth was monitored every three days as described above. The 329 
overall survival of the mice was monitored over a 90-day period. The tumor-free incidence 330 
on April 8, 2020. © 2020 American Association for Cancer Research. cancerimmunolres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on March 3, 2020; DOI: 10.1158/2326-6066.CIR-19-0628 
16 
 
is presented as the percentage of tumor-free mice among the total treated mice. 331 
For a mixed competition assay, equal numbers of EGFP- and mRuby3-positive cells were 332 
mixed together, and 5×10
6 
cells in 100 µl of sterile PBS were injected s.c. into the flank of 333 
6-week-old female C57BL/6 mice. After ten days, when the tumors reached an average 334 
size of ~100 mm
3
, OVH was administered via intratumoral injection at a dose of 1×10
7
 335 
PFU and in 50 μl of sterile PBS. Seven days after virus injection, the percentage of CD45- 336 
fluorescent cells in the tumors was calculated by flow cytometry analysis. 337 
For tumor rechallenge experiments, naive C57BL/6 mice and Hepa1-6 tumor-free 338 
C57BL/6 mice treated by virotherapy that survived for 90 days were s.c. rechallenged with 339 
5×10
7
 Hepa1-6 cancer cells in the different sites as the primary tumors. The incidence of 340 
secondary challenge rejection is presented as the percentage of tumor-free mice among 341 
the total rechallenged mice. 342 
For comparing the therapeutic efficacy of OVH plus anti-PD-1 blockers with OVH-aMPD-1 343 
therapy, virus (1×10
7 PFU) and 10 μg of aMPD-1 scFv in 50 μl of sterile PBS was 344 
intratumorally injected at day 10 and every 3 days thereafter until three doses were 345 
administered. 346 
For combinatorial therapy, virus (1×10
7 
PFU) was intratumorally injected in a volume of 50 347 
μl, and 200 μg of anti-Tigit antibody (clone 1G9, BioXcell) or rat IgG isotype control 348 
antibodies in 100 μl of sterile PBS were intraperitoneally (i.p.) injected at day 14 and every 349 
3 days thereafter until three doses were administered.  350 
For the establishment of intraperitoneal MC38 tumors, an inoculum of 1×10
6
 murine 351 
MC38 cells in 200 µl of sterile PBS was injected i.p. into 6-week-old female C57BL/6 mice. 352 
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The mice were randomized into treatment groups on day 7 following tumor inoculation, 353 
immediately before treatment. Virus (1×10
7 
PFU) in 100 μl of sterile PBS and anti-Tigit 354 
antibodies (200 μg) in 100 μl of sterile PBS were administered via i.p. injection every three 355 
days for three doses in total. The overall survival of the mice was monitored over a 356 
100-day period. 357 
Depletions 358 
Depletion of immune cells was performed with corresponding depleting rat mAbs against 359 
different immune markers. When the tumors reached 130 mm
3
, all depleting antibodies 360 
(anti-CD8α (clone 2.43, BioXcell), anti-CD4 (clone GK1.5, BioXcell) and rat IgG isotype 361 
control antibodies) were i.p. administered beginning 2 days before initiation of therapy, at 362 
a dose of 400 μg per antibody every two days  in 100 μl of sterile PBS for four dosages 363 
and thereafter every five days until the end of the experiment. Virus (5×10
6 
PFU) in 50 μl 364 
of sterile PBS was administered via intratumoral injection into the right flank tumors every 365 
three days for three doses in total. The tumor size was monitored for 24 days as described 366 
above. 367 
Bioluminescence imaging 368 
Mice that received OVH-aMPD-1 therapy were imaged every day until day 6. Mice were 369 
injected retro-orbitally with 50 μl of 40 mg/ml luciferin (E1605, Promega) in PBS and 370 
imaged immediately using the IVIS Imaging System (Caliper Life Sciences). Cells infected 371 
with OVH-aMPD-1 at different MOIs were incubated with 1ug/mL luciferin in PBS and 372 
imaged immediately using the IVIS Imaging System (Caliper Life Sciences). 373 
Immunohistochemistry 374 
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Tumors were collected at sacrifice and kept in 10% buffered formalin. The fixed tissues 375 
were histologically analyzed by immunohistochemistry (IHC) staining of indicated markers. 376 
Anti-CD8α (98941)and anti-Ki67 (12202) were obtained from Cell Signaling Technology. 377 
Anti-CD155 (LS-B10536) was obtained from LSbio.  IHC staining was performed using 378 
an Ultrasensitive SP kit (KIT-9720, Maxim) and a DAB detection kit (DAB-0031, Maxim) 379 
according to the manufacturer’s instructions.  Images were taken with a research-level 380 
upright microscope (BX51, Olympus) and data were analyzed by cellSens Standard 381 
Ver.1.4 software. 382 
Statistics 383 
Statistical significance was calculated using Student’s t test or repeated-measure ANOVA, 384 
as indicated in the figure legends. Data for survival were analyzed by the log-rank 385 
(Mantel-Cox) test. For all statistical analyses, differences were considered significant 386 
when the P value was less than or equal to 0.05. (*P < 0.05; **P < 0.01; ***P < 0.001; ****P 387 
< 0.0001; ns, not significant). Statistical analyses were performed using GraphPad Prism 388 
7. The numbers of animals included in the study are discussed in each figure. 389 
 390 
Results 391 
OVH upregulated PD-L1 expression in the TME 392 
To characterize the immunomodulatory effect of intratumoral OVH therapy, we used a 393 
Hepa1-6 liver cancer model and analyzed the tumor-infiltrating lymphocytes (TILs) within 394 
the tumor tissue after treatment (Fig. 1a). Analysis of virus-injected tumors revealed an 395 
increased inflammatory response in the tumors, showing increased infiltration of CD45
+
 396 
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leukocytes and CD3
+
 lymphocytes (Supplemental Fig. S3, a-c). Notably, there were 397 
substantial increases in the absolute numbers of CD4
+
 and CD8
+
 T cells (Fig. 1b). CD45
- 
398 
tumor cells, MDSCs, and dendritic cells (DCs) isolated from the injected and distant 399 
tumors had increased expression of PD-L1 (Fig. 1c and d); tumor-associated 400 
macrophages (TAMs) isolated from the injected tumors, but not those from distant tumors, 401 
also has increased PD-L1 expression (Supplemental Fig. S4a, b and c). Given the 402 
existing upregulation of PD-L1 expression with OVH treatment, we chose to explore 403 
whether PD-L1 on CD45
-
 tumor cells could directly attenuate the increased immune 404 
response induced by OVH, resulting in the resumption of rapid tumor cell growth. We 405 
used a mixed competition assay to test this idea by injecting C57BL/6 mice with mixtures 406 
of equivalent numbers of Hepa1-6 wild-type cells that stably expressed mRuby3 and 407 
Hepa1-6 PD-L1 knockout (KO) cells that stably expressed EGFP. At 7 days post OVH 408 
injection, we measured the cellular composition of the tumors by assessing the 409 
fluorescence of the different markers ex vivo (Fig. 1e and Supplemental Fig. S5, a and b). 410 
We hypothesized that if PD-L1 was critical for the direct suppression of the CD8
+ 
T cell 411 
cytotoxicity mediated by OVH, then the Hepa1-6 PD-L1 KO cells would be selectively 412 
depleted. Indeed, the PD-L1 KO cells were selectively reduced in tumors (Fig. 1f). These 413 
findings provided rationale for targeting the PD-1/PD-L1 axis directly in tumors, which was 414 
further supported by studies demonstrating that PD-L1 blockade can potentiate the 415 
efficacy of oncolytic virotherapy(7,8).  416 
OVH-induced type I interferon led to upregulation of PD-L1 in tumor cells 417 
We used GFP-expressing OVH as a tool to investigate the PD-L1 expression of 418 
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virus-infected and noninfected cancer cells (Fig. 2a). We found that the infection of mouse 419 
tumor cell lines with OVH induced marked PD-L1 upregulation on the surface of both 420 
virus-infected and noninfected cells. The intensity of PD-L1 staining was higher in the 421 
fraction of virus-infected cells than in that of noninfected cells, suggesting that PD-L1 422 
upregulation was mediated by two mechanisms: direct infection by the virus and an 423 
unknown indirect mechanism (Fig. 2b and c). We hypothesized that the upregulation of 424 
PD-L1 in noninfected cells after OVH infection was probably mediated by in situ secreted 425 
immune factors. Therefore, we collected UV-inactivated cell culture supernatants from the 426 
infected cells, transferred it to noninfected cells, and detected PD-L1 expression. We 427 
found that conditioned medium generated from different cancer cell lines by exposure to 428 
virus induced PD-L1 upregulation on the cell surface irrespective of the cancer cell type 429 
(Fig. 2d and Supplemental Fig. S6). These findings suggested that secreted immune 430 
factors may have promoted the upregulation of PD-L1 expression on other cells in a 431 
paracrine fashion. We hypothesized that cytokines may play a major role in PD-L1 432 
upregulation after exposure to OVH, thus treated tumor cells with different cytokines. 433 
Treatment of cancer cells with interferons (IFNs) resulted in efficient PD-L1 upregulation, 434 
with IFN-γ inducing the most robust PD-L1 upregulation (Fig. 2e and f). To confirm that 435 
type I IFN was the regulator of the PD-L1 increase, we treated cells with UV-inactivated 436 
cell culture supernatants from infected cells in the presence of an antibody blocking 437 
IFNAR or a control antibody. IFN-α, but not IFN-γ, was detected in the transferred 438 
supernatants from OVH-infected Hepa1-6 cells (Supplemental Fig. S7a and b). IFNAR 439 
antibody blockade resulted in complete abrogation of PD-L1 upregulation by OVH 440 
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treatment (Fig. 2g), confirming that type I IFN was responsible for the OVH-mediated 441 
PD-L1 upregulation observed in vitro. Furthermore, we used tumor cells and a T cell 442 
coculture assay to confirm that type II IFN was the regulator of the PD-L1 increase. We 443 
cocultured cancer cells with inactivated T cells or activated T cells in the presence of an 444 
antibody blocking IFN-γ or a control antibody (Supplemental Fig. S7c). IFN-γ antibody 445 
blockade resulted in significantly reduced PD-L1 expression (Fig. 2h). We next sought to 446 
determine whether IFN-γ could be induced by OVH in vivo (Fig. 2i). Intratumoral treatment 447 
of tumors with OVH resulted in the induction of IFN-γ expression in the treated tumors (Fig. 448 
2j). These findings highlighted the idea that OVH-induced IFN responses can drive PD-L1 449 
expression and possibly elicit adaptive immune resistance.  450 
 451 
Generation of a recombinant OVH expressing an scFv against murine PD-1 452 
To target PD-1 directly within tumors, we engineered a recombinant OVH encoding an 453 
aMPD-1 scFv (OVH-aMPD-1) (Fig. 3a). The blocking ability of aMPD-1 scFv in inhibiting 454 
the interaction between PD-1 and PD-L1 was similar to the other well-known commercial 455 
antibodies (RMP1-14 and J43), and aMPD-1 scFv specifically recognized mouse PD-1 456 
(Supplemental Fig. S8a and b). The recombinant viruses were verified by examining viral 457 
genes and exogenous gene expression (Fig. 3b). Further in vitro characterization of 458 
OVH-aMPD-1 revealed that the virus was equivalent to the parental OVH strain in regards 459 
to its replicative capacity (Fig. 3c) and cell-killing ability (Fig. 3d) in U-2 OS cells. 460 
OVH-aMPD-1 possessed significant cell-killing activity against Hepa1-6 cells and MC38 461 
cells (Supplemental Fig. S9). Infection of U-2 OS cells with OVH-aMPD-1 resulted in an 462 
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over 1,000-fold increase in aMPD-1 scFv in the supernatant of the infected cells in a 463 
time-dependent fashion (Fig. 3e). The expression of aMPD-1 scFv was relatively higher in 464 
human cancer cells than in mouse cancer cells possibly due to the relatively low 465 
permissivity of mouse cancer cells to HSV-1 (Fig. 3f). As expression was most efficient in 466 
Hepa1-6 cells, this cell line was selected as the primary model for in vivo studies. 467 
Intratumoral administration of OVH-aMPD-1 into Hepa1-6 tumors resulted in significant 468 
aMPD-1 scFv expression in treated tumors in a time-dependent fashion (Fig. 3g). Finally, 469 
we confirmed the T cell-stimulating property of recombinant aMPD-1 scFv purified from a 470 
virus-infected cell culture (Fig. 3h and Supplemental Fig. S10). 471 
 472 
OVH-aMPD-1 improved DC cell presentation and revived T lymphocytes 473 
Studies indicate that PD-1 expression by TAMs significantly inhibits phagocytosis and 474 
antitumor immunity(21), suggesting that PD-1 blockade may restore phagocytosis. We 475 
wondered whether aMPD-1 scFv derived from OVH-aMPD-1 infection could promote 476 
phagocytosis, and thus we used an in vitro phagocytosis assay to test this idea using DCs. 477 
The results revealed that the phagocytosis of cancer cells by DCs was significantly 478 
increased when cancer cells were preinfected with virus, and OVH-aMPD-1 induced 479 
much stronger phagocytosis than OVH (Fig. 3i and j; Supplemental Fig. S11a). To 480 
determine if aMPD-1 scFv secreted from OVH-aMPD-1-infected tumor cells could prevent 481 
CD3
+
 T cells exhaustion by reversing PD-1-mediated immune inhibition, we used 482 
Hepa1-6 cells and a T cell coculture assay. Compared to the OVH-treated supernatants, 483 
the OVH-aMPD-1-treated supernatants significantly increased the percentages of CD4
+
 484 
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and CD8
+
 T cells with upregulation of ICOS and CD69 expression (Fig 3k and l). 485 
Compared to the OVH-treated supernatants, the OVH-aMPD-1-treated supernatants also 486 
significantly increased the IFN-γ secretion of CD8+ T cells (Fig 3m). These in vitro results 487 
indicated that aMPD-1 scFv expression from OVH-aMPD-1 led to an enhanced cytotoxic 488 
killing ability in T cells.  489 
Next, we asked if OVH-aMPD-1 enhanced phagocytosis could improve presentation by 490 
DCs. To analyze cross-presentation by APCs induced by OVH-aMPD-1 in vivo, tumors 491 
were harvested as described in Fig. 3n. Our results showed that OVH-aMPD-1 and OVH 492 
significantly increased the ability of APCs to cross-present the MHC-I-restricted 493 
OVA-derived SIINFEKL peptides (Fig.3o and Supplemental Fig. S11b), which may be 494 
conducive to the activation of tumor-specific CD8
+
 T cells. OVH-aMPD-1 exhibited 495 
relatively excellent DC cell presentation in vivo. These results indicated that OVH-aMPD-1 496 
treatment led to improved antigen presentation by DCs. 497 
 498 
OVH-aMPD-1 induced immunogenic cell death in murine cancer cells 499 
OVH-aMPD-1-infected tumor cells promoted phagocytosis, thus improving antigen 500 
presentation by DCs. To understand why we first dissected the cell death pattern induced 501 
by OVs. We tested the activity of the apoptotic executioner caspase-3 and apoptotic 502 
marker PARP. The cleaved forms of both markers were increased after either OVH 503 
infection or OVH-aMPD-1 infection (Supplemental Fig. S12a), indicating that OV-induced 504 
oncolysis could lead to apoptotic cell death. To determine the immunogenicity of 505 
OV-treated cancer cell lines, and the infected cells and supernatants were harvested and 506 
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analyzed for expression of immunogenic cell death (ICD)-associated damage-associated 507 
molecular patterns (DAMPs). The levels of secreted ATP, surface expressed calreticulin, 508 
and secreted HMGB1 were upregulated in the OVH-infected cancer cells and 509 
OVH-aMPD-1-infected cancer cells (Supplemental Fig. S12, b to d). Our study revealed 510 
that OVH and OVH-aMPD-1 both induced ICD in murine cancer cells, thus leading to DC 511 
stimulation. We observed OVH-aMPD-1 induced stronger antigen presentation by DCs 512 
than OVH, which may be associated with the expression of aMPD-1 scFv. 513 
 514 
OVH-aMPD-1 improved tumor control and enhanced effector T cell function 515 
To further evaluate the antitumor potential of OVH-aMPD-1 in vivo, we used a preclinical 516 
murine tumor model bearing bilateral Hepa1-6 tumors (Fig. 4a), which were treated with 517 
three consecutive intratumoral OV injections. We first excluded the possibility of direct 518 
virus infection of untreated tumor on the distant flank  (Supplemental Fig. S13, a to g). It 519 
was observed that bilateral tumor growth was significantly inhibited both in the 520 
OVH-treated group and OVH-aMPD-1-treated group (Fig. 4b and c), and there was no 521 
significant difference in tumor size reduction between these two groups. However, more 522 
long-term tumor regression was observed in the OVH-aMPD-1-treated group than in the 523 
OVH-treated group (Fig. 4d to j). Long-term survivors that rejected primary tumors also 524 
rejected a second challenge with a larger amount of Hepa1-6 tumor cells (Fig. 4k). These 525 
results showed that OVH-aMPD-1 exhibited relatively excellent therapeutic efficacy in vivo, 526 
which led to complete tumor rejection. However, both OVH-aMPD-1 and OVH were 527 
comparable in their ability to cause tumor regression in immunodeficient nude mice (Fig. 528 
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4l), suggesting that intratumoral aMPD-1 scFv expression from OVH-aMPD-1 led to 529 
enhanced therapeutic effects only in immunocompetent tumor models. Additionally, we 530 
compared the therapeutic efficacy of OVH plus anti-PD-1 blockers with OVH-aMPD-1 531 
monotherapy. There was no significant difference in therapeutic efficacy between these 532 
two groups (Fig. 4m-o), further supporting the benefits of OVH-aMPD1 as a single agent 533 
to treat tumor. 534 
To investigate the molecular mechanisms underlying OVH-aMPD-1 mediated tumor 535 
control, we analyzed the inflammatory response within tumors (Fig. 5a). Increased 536 
infiltration of adaptive cells, including CD4
+
 and CD8
+
 lymphocytes, was observed in 537 
tumors (Fig. 5b and c), suggesting that abundant immune infiltrates were recruited into the 538 
injected tumors and distant tumors treated with either OVH or OVH-aMPD-1. When 539 
compared with those isolated from OVH-injected and distal tumors, the CD4
+
 and CD8
+
 T 540 
cells isolated from the OVH-aMPD-1-injected and distal tumors expressed significantly 541 
more of the activation markers ICOS and CD69 (Fig. 5d and e), suggesting that 542 
OVH-aMPD-1 enhanced effector T cell function. It seemed that more pronounced ICOS
+
 543 
CD8
+ 
T cells were infiltrated in the distant tumors compared to the OVH-injected tumors 544 
(Fig. 5d and e). These results indicated that OVH-aMPD-1 virotherapy could remodel the 545 
TME and lead to the activation of intratumoral T cells. 546 
Despite the significant T cell activation observed after intratumoral administration of 547 
OVH-aMPD-1, the magnitude of the effect was dependent on tumor size (Supplemental 548 
Fig. S14a and b), suggesting that additional inhibitory mechanisms within the TME 549 
prevent complete tumor rejection in large advanced tumor. We carried out IHC staining to 550 
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analyze the histological changes within the tumor tissue before and after treatment (Fig. 551 
5f). OVH and OVH-aMPD-1 treatment induced CD8
+
 T cells infiltration into the 552 
virus-injected tumors and distant tumors (Fig. 5f). Significant upregulation of CD155 and s 553 
ignificant reduction in proliferation signals (Ki67) were observed in the virus-injected 554 
tumors and distant tumors (Supplemental Fig. S15a and b), which suggested immune 555 
mediated tumor inhibition 556 
 557 
OVH-aMPD-1 potentiated the efficacy of TIGIT blockade 558 
Analysis of TILs from virus-injected and distant tumors revealed that the immune infiltrates 559 
were characterized by an increase in CD11b
+
 Gr-1
+
 MDSCs (Fig. 6a and Supplemental 560 
Fig. S16a). Significantly higher amounts of MDSCs were observed in both the 561 
OVH-aMPD-1-injected and distal tumors compared to the OVH-injected and distal tumors. 562 
The percentage of intratumorally CD155
+
 G-MDSCs and CD155
+
 M-MDSCs were 563 
significantly higher in both the OVH-aMPD-1-injected and distal tumors compared in the 564 
OVH-injected and distal tumors (Fig. 6b and c; Supplemental Fig. S17a and b). The 565 
upregulation of CD155 expression on tumor cells was not observed in either the 566 
OVH-treated group or the OVH-aMPD-1-treated group (Supplemental Fig. S17c). 567 
We thus evaluated the efficacy of combination therapy using TIGIT blockade and 568 
virotherapy. Combination therapy with OVH-aMPD-1 and an anti-TIGIT antibody led to 569 
regression of the virus-injected tumors and distant tumors, which was superior to the 570 
combination of OVH and TIGIT blockade (Fig. 6d, e and f). To validate these findings in 571 
other tumor models, we used the peritoneal MC38 colon carcinoma model (Fig. 6g). 572 
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MC38 cell line exhibited relatively lower sensitivity to OVs infection, resulting in lower 573 
expression of aMPD-1 scFv (Fig. 3f and Supplemental Fig. S18). In the MC38 model, the 574 
combination of OVH-aMPD-1 and TIGIT blockade was superior to both monotherapies 575 
(OVH or TIGIT blockade) and combination therapy (OVH with TIGIT blockade) (Fig. 6h). 576 
OVH-aMPD-1 synergized with TIGIT blockade, leading to long-term management of the 577 
invasive tumors.  578 
We carried out depletion experiments to analyze whether CD4
+
 or CD8
+
 T cells were 579 
critical for mediating antitumor effects in non-injected tumors (Fig. 6i and Fig. S19). 580 
Depletion of CD8
+
 T cells or CD4
+
 T cells in vivo impaired the therapeutic efficacy of 581 
combination therapy with OVH-aMPD-1 and an anti-TIGIT antibody (Fig. 6j and k).  582 
When CD8
+
 T cells were depleted in the mice treated with the OV, tumors progressed 583 
more rapidly when compared to mice with depletion of CD4+ T cells (Fig. 6j and k). These 584 
results demonstrated that CD4
+
 or CD8
+
 T cells were critical for mediating tumor 585 
regression of both injected tumors and distant tumors. 586 
 587 
Combination therapy increased tumor-specific CD8
+
 T cell responses. 588 
To investigate the immune mechanisms underlying the antitumor efficacy of the 589 
combination therapy of TIGIT blockade and OVH-aMPD-1 virotherapy, we used a 590 
Hepa1-6-OVA cancer model and analyzed the infiltration of CD8
+
 T lymphocytes and 591 
tumor-specific CD8
+
 T lymphocytes in tumors and the spleen (Fig. 7a). Increased 592 
infiltration of CD8
+
 T lymphocytes was observed in the tumors treated with either OV, 593 
TIGIT blockade or combination therapy (Fig. 7b and c). TIGIT blockade could facilitate 594 
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CD8
+
 lymphocyte infiltration regardless of whether OVs were administered, and the 595 
percentage of intratumorally infiltrated CD8
+
 T lymphocytes was significantly higher in the 596 
mice receiving combination therapy with TIGIT blockade and OVH-aMPD-1 virotherapy 597 
than those receiving combination therapy with TIGIT blockade and OVH virotherapy. In 598 
addition, compared with each monotherapy or combination therapy with TIGIT blockade 599 
and OVH virotherapy, combination therapy with TIGIT blockade and OVH-aMPD-1 600 
virotherapy significantly increased the accumulation of tumor-specific CD8
+
 T 601 
lymphocytes (Fig. 7d and Supplemental Fig. S20). Increased accumulation of 602 
tumor-specific CD8
+
 T lymphocytes was observed in the tumors and spleens isolated from 603 
the mice treated with either OVH-aMPD-1 virotherapy or combination therapy with TIGIT 604 
blockade and OVH-aMPD-1 virotherapy (Fig. 7e and f). TIGIT blockade could facilitate 605 
CD8
+
 T lymphocyte infiltration into the spleens only when OVH-aMPD-1 was administered, 606 
and the percentage of splenic tumor-specific CD8
+
 T lymphocytes was slightly higher in 607 
the mice receiving combination therapy with TIGIT blockade and OVH-aMPD-1 608 
virotherapy than in those receiving combination therapy with TIGIT blockade and OVH 609 
virotherapy. These in vivo results indicated that aMPD-1 scFv expression from 610 
OVH-aMPD-1, together with TIGIT blockade, led to significantly increased numbers of 611 
tumor-specific CD8
+
 lymphocytes, correlating to rejection of established tumors. 612 
 613 
Discussion 614 
Treatment options and their outcomes in several tumor indications, such as melanoma 615 
and small cell lung cancer, have changed significantly. Immunotherapy has become the 616 
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first-line therapy for several subsets of patients with a high tumor mutational burden, 617 
microsatellite instability or PD-L1 expression, including melanoma, non–small cell lung 618 
cancer (NSCLC), colorectal cancer, and urothelial cancer (24). However, the clinical 619 
efficacy of immunotherapy is still limited, and a large proportion of patients with advanced 620 
cancer do not benefit from current immunotherapeutic strategies(25). Combination 621 
therapy with anti-CTLA-4 and anti-PD-1 inhibitors has been suggested as a potential 622 
efficacious treatment option for advanced melanoma; however, the potential toxicities of 623 
this form of combinatorial immunotherapy is still the largest concern for its clinical 624 
application(26,27). There is still an urgent need for improved agents for long-term tumor 625 
control. Therefore, the aim of this study was to use an engineered multiplexed OV to 626 
improve the potential of oncolytic virotherapy as a standalone therapeutic approach. 627 
 628 
Our rationale for constructing an armed OV that can mediate immune checkpoint 629 
blockade was that OVH induced strong upregulation of PD-L1 expression in the TME. A 630 
similar strategy has been successful in human melanoma patients, where talimogene 631 
laherparepvec (T-VEC, armed with GM-CSF) improves antitumor efficacy mediated with 632 
GM-CSF-enhancing immune response(28). GM-CSF is an immune stimulator that 633 
promotes the differentiation of progenitor cells into DCs and shows a certain degree of 634 
antitumor efficacy in clinical trials. The combination of GM-CSF with oncolytic therapy may 635 
provide an in situ antitumor vaccine by enhancing tumor antigen presentation. 636 
Furthermore, intratumoral T-VEC therapy in combination with systemic anti-PD-1 therapy 637 
significantly increases overall response rate (62%) in metastatic melanoma patients(10). 638 
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However, in a randomized open-label phase III trial, 26.4% of the patients in the T-VEC 639 
alone arm had an objective response(29). Other studies also suggest that oncolytic 640 
virotherapy may improve the efficacy of immune checkpoint blockade by changing the 641 
TME(30). These findings highlight that combinatorial regimens can achieve efficacy 642 
superior to that of monotherapy. We thus hypothesized that constructing an OV, 643 
expressing a PD-1-blocking scFv would provide combinatorial immunotherapy and 644 
localized delivery of aMPD-1 scFv in the TME. 645 
 646 
It is intriguing that this antitumor activity was dependent on the expression of aMPD-1 647 
scFv within the TME. The limits of this study were the inherent poor replication of 648 
OVH-aMPD-1 in murine cancer cells and thus the low production of aMPD-1 scFv in 649 
mouse tumors. A major reason for the short-term life cycle of OVH-aMPD-1 in treated 650 
mice, which was closely related to the in vivo dynamic kinetics of aMPD-1 scFv 651 
expression, is likely to be the relatively low permissiveness of immunocompetent mice, 652 
especially C57BL/6 mice, to HSV-1 infection(31,32). This observation suggests that 653 
inadequate replication of OVH-aMPD-1 reduces the expression of aMPD-1 scFv and thus 654 
restricts combinatorial antitumor effects. Despite this possible replicative defect, 655 
compared to its parental virus, OVH-aMPD-1 significantly reduced tumor sizes and 656 
extended survival. 657 
 658 
Another possible concern was that aMPD-1 scFv reacted only with PD-1 of mouse origin 659 
due to the homology disparity between mouse and human PD-1 sequences, which share 660 
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approximately 61.1% amino acid identity in the extracellular domains(33). To our 661 
knowledge, it is difficult to obtain an antibody that recognizes both human and mouse 662 
PD-1 with high affinity and blocking activity, and the activity of an antibody may determine 663 
its antitumor activity. Although, aMPD-1 scFv that can bind to PD-1 of both mouse and 664 
human origin exists, but whether this aMPD-1 scFv can execute immunomodulatory 665 
functions has not been fully addressed(34). For further clinical investigation, we should 666 
construct an OV arming with a humanized antibody that recognizes human PD-1. 667 
 668 
In addition to inducing ICD, OVs can induce the release of tumor antigens, which 669 
facilitates the initiation of a tumor-antigen specific response within a tumor(35). Our study 670 
revealed that OVH-aMPD-1 could not only release immunogenic DAMPs but also 671 
significantly promote antigen cross-presentation by DCs. The importance of presentation 672 
by DCs in initiating a durable T cell response has previously been demonstrated(36,37), 673 
and in situ aMPD-1 scFv expression may enhance tumor-antigen specific T cell 674 
responses by promoting efficient presentation of antigens to T cells. 675 
 676 
The highly immunosuppressive TME may require a more complex immunotherapeutic 677 
strategy(38). Although HSV-1 vectors are emerging as an effective therapeutic approach 678 
for cancer, it is ultimately cleared by the host immune system before complete tumor 679 
clearance(13). Thus, it is vital to develop rational combinatorial strategies to overcome the 680 
highly immunosuppressive TME(39,40). Our rationale for designing combinatorial 681 
strategies using OVH-aMPD-1 armed for immune checkpoint blockade was that 682 
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OVH-aMPD-1 induced significantly higher percentages of CD155
+
 G-MDSCs and 683 
M-MDSCs in tumors. Given that CD155-TIGIT signaling exerts potent inhibitory action in 684 
different subsets of immune cells(41,42), this study points toward a  promising 685 
therapeutic strategy to combine OVH-aMPD-1 with TIGIT blocking agents. Our study 686 
revealed that the combination of a virus expressing aMPD-1 scFv with TIGIT blockade 687 
significantly improved therapeutic efficacy; however, TIGIT blockade did not improve the 688 
antitumor effect of OVH virotherapy. Therefore, in situ aMPD-1 scFv expression together 689 
with TIGIT blockade further enhanced the locoregional and systemic tumor 690 
antigen-specific T cell response. These findings suggest that the magnitude and efficacy 691 
of TME remodeling and T cell activation induced by a multifaceted oncolytic vector may 692 
potentiate the efficacy of immune checkpoint blockade. 693 
 694 
In summary, our data demonstrated that OVH-aMPD-1 virotherapy was an effective 695 
strategy for aMPD-1 scFv delivery and treatment, TME remodeling, improving antigen 696 
cross-presentation in DCs and inducing antitumor T cell immunity. To further overcome 697 
the highly immunosuppressive TME, OVH-aMPD-1 synergized with TIGIT blockade, 698 
which lead to the long-term control of invasive tumors. The findings from this study 699 
provide a rationale for the combination of a novel OV armed with immunotherapeutics with 700 
immune checkpoint blockade for the treatment of advanced cancer. 701 
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Figure Legends 846 
 847 
Figure 1. OVH induced the upregulation of PD-L1 expression in the tumor 848 
microenvironment 849 
(a) Treatment scheme for Hepa1-6 hepatoma-bearing mice; s.c., subcutaneously. (b) 850 
Absolute numbers of tumor-infiltrating CD4
+
 and CD8
+
 T cells isolated from vehicle (PBS) 851 
or OVH-injected tumors and distant tumors. (c) Expression of PD-L1 on the surface of 852 
CD45
-
 cancer cells and MDSC cells in tumors. (d) Expression of PD-L1 on the surface of 853 
DCs in tumors. (e) Control Hepa1-6 and Hepa1-6 PD-L1
KO
 tumor cells that stably express 854 
mRuby3 or EGFP were mixed at a 1:1 ratio (input) and inoculated s.c. into mice. 855 
Representative plots gated on live CD45
−
 fluorescent cells showing the frequencies of 856 
mRuby3
+
 and EGFP
+
 cells, among live CD45
− 
fluorescent cells. (f) Ratio of the 857 
frequencies of mRuby3
+ 
and GFP
+
 tumor cells in the vehicle or virus-injected tumors. 858 
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Triplicates were performed for each experiment and values are the means of three 859 
independent experiments (a-f). All values are presented as the mean ± SEM. Statistical 860 
analysis was performed using an unpaired two-tailed Student’s t tests (b-d); *P < 0.05, **P 861 
< 0.01, ***P < 0.001, and ****P < 0.0001. 862 
 863 
Figure 2. Upregulation of PD-L1 expression in tumor cells by OVH-induced IFNs 864 
(a) Treatment scheme for OVH infection and PD-L1 analysis. (b) PD-L1 expression in 865 
OVH-infected (GFP
+
) and noninfected (GFP
-
) Hepa1-6 cells (MOI=5). Representative 866 
histograms for Hepa1-6 cells and MC38 cells are shown. (c) Quantification of the PD-L1 867 
MFI in different infected cell lines. (d) PD-L1 upregulation in MC38 cells or Hepa1-6 cells 868 
treated with UV-inactivated supernatants from vehicle (PBS)-treated or OVH-infected cells 869 
(MOI=5). (e) Upregulation of PD-L1 expression in Hepa1-6 cells in response to treatment 870 
with recombinant cytokines. (f) Upregulation of PD-L1 expression in MC38 cells in 871 
response to treatment with recombinant cytokines. (g) Inhibition of PD-L1 upregulation by 872 
an IgG antibody or IFNAR antibody in Hepa1-6 cells treated with UV-inactivated 873 
supernatants from vehicle-treated or OVH-infected cells. (h) Inhibition of PD-L1 874 
upregulation by an IgG antibody or IFN-γ antibody in cocultures of either CD3/CD28 875 
antibody-activated T cells or inactivated T cells and Hepa1-6 cells treated with 876 
UV-inactivated supernatants from OVH-infected cells. (i) Treatment scheme for IFN-γ 877 
detection in tumors in response to OVs treatment. (j) Expression of IFN-γ in vehicle- and 878 
OVH-treated Hepa1-6 tumors at 12, 24 and 36 h post treatment. Triplicates were 879 
performed for each experiment and values are the means of three independent 880 
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experiments (b-h). Data represent results from one of three independent experiments with 881 
n=5 per group (j). All values are presented as the mean ± SEM. Statistical analysis was 882 
performed using one-way ANOVA (c, e-j) or an unpaired two-tailed Student’s t test (d); *P 883 
< 0.05, **P < 0.01, ***P < 0.001 and ****P < 0.0001.. 884 
 885 
Figure 3. An oncolytic herpes virus expressing a recombinant scFv against murine 886 
PD-1 (OVH-aMPD-1), improved presentation by DCs and revived T lymphocytes 887 
(a) OVH-aMPD-1 genomic construct scheme. (b) Western blot analysis of various proteins 888 
in virus-infected cells. (c) Replication of the parental OVH strain and OVH-aMPD-1 in 889 
Hepa1-6 cells. (d) In vitro cell killing of U-2 OS cells by OVH or OVH-aMPD-1 infection. (e) 890 
Expression of aMPD-1 scFv in U-2 OS cells at different time points (MOI=1). (f) 891 
Expression of aMPD-1 scFv in human and mouse cancer cell lines at 24 h post infection 892 
(MOI=1). (g) Expression of aMPD-1 scFv in tumors after OVH or OVH-aMPD-1 treatment, 893 
n=6. (h) Activation of T cells by aMPD-1 scFv purified from supernatants of 894 
OVH-aMPD-1-infected cells. (i-j) DCs cultured overnight with MC38-mRuby3 or 895 
Hepa1-6-mRuby3 cells pretreated with vehicle, OVH or OVH-aMPD-1 for 24 h. 896 
Frequencies of CD11c
+ 
mRuby
+
 MC38 cells (i) and CD11c
+ 
mRuby
+ 
Hepa1-6 cells (j). (k-m) 897 
Activated T cells coculture with 5×10
4
 irradiated Hepa1-6 cells and supernatants from 898 
PBS-, OVH- and OVH-aMPD-1 treated cells at 48 h post infection. The percentages of 899 
CD69
+
 and ICOS
+
 cells among the CD4
+
 T cells (k) and CD8
+
 T cells (l) analyzed by flow 900 
cytometry analysis, and the amount of released IFN-γ in the medium (m). (n) 901 
Experimental design for analyzing APC cross presentation in vivo. C57BL/6J mice were 902 
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implanted s.c with Hepa1-6-OVA cells on right flank. Tumors were intratumorally treated 903 
with OVs (1×10
7
PFU) or PBS (vehicle) for two doses on day 15 and 18. Tumors isolated 904 
from mice were dissociated and analyzed by flow cytometry on day 21. (o) The 905 
percentages of H-2Kb/SIINFEKL
+
 cells among the CD11c
+
MHC-I
+
 cell population. 906 
Triplicates were performed for each experiment and values are the means of three 907 
independent experiments (c-m). Data represent results from one of two independent 908 
experiments with n=6 per group (o). All values are presented as the mean ± SEM. 909 
Statistical analysis was performed using one-way ANOVA (h-m, o)*P < 0.05, **P < 0.01, 910 
***P < 0.001, and ****P < 0.0001. 911 
 912 
Figure 4. OVH-aMPD-1 improved both local and systemic tumor control 913 
(a) Treatment scheme. (b, c) Growth of vehicle (PBS)-, OVH- and OVH-aMPD-1-treated 914 
syngeneic Hepa1-6 tumors in immunocompetent C57BL/6 mice (n=9). Tumor growth of 915 
injected (right flank) Hepa1-6 tumors (b) and distant (left flank) Hepa1-6 tumors (c). (d-f) 916 
Individual tumor growth curves of vehicle (PBS)-, OVH- and OVH-aMPD-1-injected 917 
Hepa1-6 tumors. (g-i) Individual tumor growth curves of distant Hepa1-6 tumors. (j) 918 
Percent of tumor free mice in the Hepa1-6 liver cancer model. (k) Survival of cured 919 
Hepa1-6 model survivors rechallenged with 5×10
7
 Hepa1-6 cells. (l) Growth of vehicle 920 
(PBS)-, OVH- or OVH-aMPD-1-treated Hepa1-6 xenografts in immunodeficient nude mice 921 
(n=6). Data for survival were analyzed by the log-rank (Mantel-Cox) test (k). (m) 922 
Treatment scheme for comparing the therapeutic efficacy of OVH plus anti-PD-1 blockers 923 
with OVH-aMPD-1 monotherapy. (n, o) Tumor growth of injected and distant Hepa1-6 924 
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tumors. Data either represent results from one of three (b-k) or one of two (l, n, o) 925 
independent experiments with n=6 to n=10 per group. All values are presented as the 926 
mean ± SEM. Statistical analysis was performed using repeated-measure ANOVA (b, c, l, 927 
n, o).*P < 0.05, **P < 0.01, and ***P < 0.001; ns, not significant.  928 
Figure 5. OVH-aMPD-1 enhanced effector T cell function 929 
(a) Treatment scheme. Mice bearing Hepa1-6 tumors were intratumorally injected with 930 
vehicle (PBS), OVH or OVH-aMPD-1, and tumors were collected on day 10 post virus 931 
injection and analyzed by flow cytometry. The percentages of tumor-infiltrating CD4
+
 T 932 
and CD8
+
 T cells isolated from the injected (b) and distant tumors (c), gated on the total 933 
CD45
+
 cell population. (d, e) Expression of CD69 and ICOS on the surface of 934 
tumor-infiltrating CD4
+ 
and CD8
+ 
T cells in the vehicle-injected or virus-injected tumors (d) 935 
and distant tumors (e). (f) IHC analysis of CD8
+
 T cells marker (CD8α) and CD155 in 936 
virus-injected tumor and distant tumor at 7 days after receiving intratumoral injection of 937 
two doses of OVH or OVH-aMPD-1 (1×10
7
 PFU per dose) or vehicle. Data either 938 
represent results from one of three (b-e) or one of two (f) independent experiments with 939 
n=5 to n=6 per group. All values are presented as the mean ± SEM. Statistical analysis 940 
was performed using one-way ANOVA; *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 941 
0.0001; ns, not significant.  942 
 943 
Figure 6. TIGIT blockade potentiated the efficacy of OVH-aMPD-1 virotherapy 944 
(a) Increase in the proportions of MDSCs in the lymphocyte populations isolated from 945 
injected and distant tumors. MDSCs, CD11b
+
 Gr-1
+
 cells. (b, c) Increase in the proportions 946 
on April 8, 2020. © 2020 American Association for Cancer Research. cancerimmunolres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on March 3, 2020; DOI: 10.1158/2326-6066.CIR-19-0628 
44 
 
of CD155
+
 G-MDSCs and M-MDSCs in injected tumors (b) and distant tumors (c). 947 
G-MDSC, granulocytic-myeloid-derived suppressor cells (CD11b
+
 Ly6C
-
 Ly6G
+
); M-MDSC, 948 
monocytic-myeloid-derived suppressor cells (CD11b
+
 Ly6C
+
 Ly6G
-
). (d) Treatment 949 
scheme. (e, f) Mice bearing Hepa1-6 tumors received monotherapy or combination 950 
therapy. Growth of injected tumors (e) and distant tumors (f). (g) Treatment scheme for 951 
establishment of intraperitoneal MC38 tumors. (h) Overall survival was monitored over a 952 
100-day period. (i) Treatment scheme for depletion experiments. (j, k) Mice bearing 953 
Hepa1-6 tumors received combination therapy and indicated depletion antibodies or 954 
isotype antibodies. Growth of injected tumors (j) and distant tumors (k). Data either 955 
represent results from one of three (a-h) or one of two (j, k) independent experiments with 956 
n=6 to n=10 per group. Data for survival were analyzed by the log-rank (Mantel-Cox) test 957 
(h). All values are presented as the mean ± SEM. Statistical analysis was performed using 958 
repeated-measure ANOVA (e, f, j, k) or one-way ANOVA (a-c); *P < 0.05, **P < 0.01, ***P 959 
< 0.001, and ****P < 0.0001; ns, not significant.. 960 
Figure 7. Combination therapy with TIGIT blockade and OVH-aMPD-1 virotherapy 961 
increased tumor antigen-specific CD8
+
 T cell responses 962 
(a) Treatment scheme. Tumors isolated from mice receiving various treatments were 963 
dissociated and analyzed by flow cytometry. (b) Percentages of CD8
+ 
T cells in the live 964 
CD45
+
 cell population. (c) Representative flow cytometry plots of CD45
+
CD8
+
 cells gated 965 
on the total live CD45
+
 cell population. (d) Representative flow cytometry plots of 966 
OVA-specific (H-2 Kb/SIINFEKL tetramer
+
) CD8
+
 cells gated on the CD8
+ 
cell population 967 
in the tumor. (e) Percentages of H-2 Kb/SIINFEKL tetramer
+ 
CD8
+
 T cells in the tumor 968 
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CD8
+ 
T cell population. (f) Percentage of H-2 Kb/SIINFEKL tetramer
+ 
CD8
+
 T cells in the 969 
splenic CD8
+ 
T cell population. Data either represent results from one of three (b, c) or 970 
one of two (d, e, f) independent experiments with n=6 per group. All values are presented 971 
as the mean ± SEM. Statistical analysis was performed using one-way ANOVA (b-d); *P < 972 
0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001; ns, not significant.. 973 
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